Abstract
BackgroundEpigenetic modifying therapies, including hypomethylating agents (HMA) and histone deacetylase (HDAC) inhibitors, have shown promising results in the treatment of acute myeloid leukemia (AML). Recent data point to an immunological...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have